Discovery of STAT3 and HDAC dual-pathway inhibitors for the treatment of solid cancer. The PK experiment in SD Rats was carried out by Medicilon

Over 20 years of experience in R&D

Learn more

01 Drug Discovery

Chemistry Research

Biology Research

Early Pharmacokinetics

02 Pharmaceutical Research

Intermediates

Active Pharmaceutical Ingredients

Pharmaceutical preparation

Analytical Method Development and Quality Control

CMC Filings

Analytical Testing Center

03 Preclinical Research

Pharmacology & Pharmacodynamics

Drug Safety Evaluation

DMPK

Bioanalysis

IND Filings

01 One-stop Integrated Services

Liposome Drug Development

Drug Discovery

Pharmaceutical Research

Preclinical Research

Botanical Drug Preclinical R&D

02 Innovative Drug Services

ADC

PROTAC

mRNA Vaccine

Cellular Immunotherapies

Nucleic Acid Drug

Peptide Drug Conjugate (PDC)

Antibody

03 Key Technical Services for Drug R&D

Cytokine and Biomarker Detection

Metabolite Identification (MetID)

Drug Forming Research

Flow Cytometry Technology

SEND Format Conversion

Flow Sorting

NanoString nCounter Detection

Routes of Drug Administration

04 Drug Efficacy Evaluation for Common Diseases

IO Pharmacodynamic Model

Inflammatory and Immune Diseases

Rodent Cerebrovascular Disease

05 Advanced Preparation R&D

Inhalation drug

Ophthalmic drug

Skin Topical Preparation

06 Targeted Drugs R&D Services

STAT3-targeted Drugs R&D Service

GLP-1 New Drug R&D Service

KRAS-targeted Drugs R&D Service

2024-07-22Medicilon Events

The Shanghai Overseas Returned Scholars Association invites the Dutch PhD delegation to visit Medicilon, exploring paths for innovative development together

On July 4th, the Shanghai Overseas Returned Scholars Association invited the Dutch PhD delegation to visit the Chuansha campus of Shanghai Medicilon Inc. (Medicilon) and held discussions with Medicilon's Founder and CEO, Chunlin Chen, among others.

Learn more

2024-07-22Medicilon Events

5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"

Medicilon stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.

Medicilon 688202

RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CLIENT CENTER

Intellectual Property Protection

U.S.

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(626)986-9880

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Shanghai Public Network Security File No. 31011502018888 | Website Map

Discovery of STAT3 and HDAC dual-pathway inhibitors for the treatment of solid cancer. The PK experiment in SD Rats was carried out by Medicilon

2023-07-11

Page View：

The inhibition of HDACs will lead to compensated activation of a notorious cancer-related drug target, STAT3, in breast cancer through a cascade, which probably limits the anti-proliferation effect of HDAC inhibitors in solid tumors. Herein, researchers synthesized a series of potent pterostilbene hydroxamic acid derivatives with dual-target inhibition activity.

The pharmacokinetic experiment in SD Rats was carried out by Medicilon.

Reference:

Yuhao Ren, et al. Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer. J Med Chem. 2021 Jun 10;64(11):7468-7482. doi: 10.1021/acs.jmedchem.1c00136.